戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ies for off-label utilization of recombinant activated factor VII.
2                         Measured were plasma activated factor VII activity (FVIIa), FVII coagulant (F
3  for hemorrhage control, such as recombinant activated factor VII and hemostatic bandages, are in dev
4  binding constants of prothrombin, factor X, activated factor VII, and activated protein C to seven d
5 s (e.g., fresh-frozen plasma and recombinant-activated factor VII) are poorly aligned with recommende
6  drotrecogin alpha (activated protein C) and activated factor VII concentrate (NovoSeven), have been
7      In a recent phase II trial, recombinant activated factor VII (eptacog alfa) reduced haematoma ex
8 ne whether these associations are related to activated factor VII (factor VIIa).
9        The factors studied were prothrombin, activated factor VII, factor IX, factor X, activated pro
10                   TF monoclonal antibody and activated factor VII (FVIIa) binding studies showed that
11    Intravenous infusion of recombinant human activated Factor VII (FVIIa) has been used for over a de
12                     Continuous expression of activated factor VII (FVIIa) via gene transfer is a pote
13                 Catalytic domain variants of activated factor VII (FVIIa) with enhanced hemostatic pr
14                    Successful competition of activated factor VII (FVIIa) with zymogen factor VII (FV
15 c tenase complexes of tissue factor (TF) and activated factor VII (FVIIa), and trigger blood coagulat
16                                  Recombinant activated factor VII has expanded available therapeutic
17 arize the safety and efficacy of recombinant activated factor VII in diverse clinical settings based
18 zed control trials investigating recombinant activated factor VII in non-hemophiliacs have been publi
19 ed the role of the tissue factor (TF)-FVIIa (activated factor VII)-integrin B1-PAR2 (protease-activat
20  Case reports would suggest that recombinant activated factor VII is an efficacious and safe "univers
21                                              Activated factor VII is approved for treating hemophilia
22                                  Recombinant activated factor VII is increasingly being used for off-
23 tion of thrombin generation with recombinant activated factor VII or activated prothrombin complex co
24 with soluble tissue factor and phospholipid, activated factor VII-Q10E32 displayed increased activati
25  trials have reported the use of recombinant-activated factor VII (rFVIIa) as an adjunct for reversal
26           Evidence suggests that recombinant activated factor VII (rFVIIa) can decrease intractable b
27   We sought to determine whether recombinant activated factor VII (rFVIIa) can reduce hematoma growth
28                                  Recombinant activated factor VII (rFVIIa) is a non-plasma-derived, r
29 onfirm a previous study in which recombinant activated factor VII (rFVIIa) reduced growth of the hema
30 alysis of safety and efficacy of recombinant activated factor VII (rFVIIa) used as the last resort fo
31 arrived the antihemophilic agent recombinant activated factor VII (rFVIIa).
32 blished as abstracts, supporting recombinant activated factor VII safety, but not its efficacy.
33                       The first step is when activated factor VII (VIIa) in the plasma binds to TF, f
34                                              Activated factor VII (VIIa) was measured in 829 men.
35 ctivity of recombinant human TF complexed to activated factor VII was inhibited by PAEC and HAEC-asso